Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01055847 · ClinicalTrials.gov registry record · Phase 2

Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection

A Phase 2 study of Cystic Fibrosis and Pseudomonas Aeruginosa, sponsored by Gilead Sciences.

Completed
Registry status
Phase 2
Development phase
105
Enrollment target
20
Study locations

NCT01055847: Completed Phase 2 study of Cystic Fibrosis and Pseudomonas Aeruginosa, sponsored by Gilead Sciences.

NCT01055847 is a Phase 2 study of Cystic Fibrosis and Pseudomonas Aeruginosa that has completed, run by Gilead Sciences. The registered enrollment target is 105 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01055847, a Phase 2 study of Cystic Fibrosis and Pseudomonas Aeruginosa, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
Phase 2
Development phase
105 participants
Enrollment target
20
Study locations

Study Summary

This is multicenter placebo-controlled study evaluating the safety and efficacy of AI at two dosage levels compared to placebo in CF patients with P. aeruginosa lung infection.

Conditions Studied

Cystic Fibrosis Pseudomonas Aeruginosa Lung Infection CF

Interventions

  • DRUG Placebo
  • DRUG Aztreonam for Inhalation (AI)

Study Locations (20)

California

  • - Los Angeles
  • - Orange
  • - San Diego
  • - Stanford

Ohio

  • - Cleveland
  • - Columbus
  • - Dayton

Florida

  • - Gainsville
  • - Orlando

Colorado

  • - Denver

Massachusetts

  • - Boston

Michigan

  • - Ann Arbor

Nebraska

  • - Omaha

North Carolina

  • - Chapel Hill

Trial Details

FieldValue
Enrollment Target 105 participants
Start Date 2003-06
Est. Completion 2004-09
Phase Phase 2
Gilead Sciences

504 total trials

What the finished NCT01055847 record still lists

NCT01055847 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (41% lower).

The record links to 4 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01055847 names 20 study sites across 14 states, led by California, Ohio, Florida.

Frequently Asked Questions

What is clinical trial NCT01055847 about?

NCT01055847 is a clinical study titled "Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection". This is multicenter placebo-controlled study evaluating the safety and efficacy of AI at two dosage levels compared to placebo in CF patients with P. aeruginosa lung infection.

What is the current status of trial NCT01055847?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2003-06. Estimated completion is 2004-09.

What conditions does trial NCT01055847 study?

This clinical trial studies the following conditions: Cystic Fibrosis, Pseudomonas Aeruginosa, Lung Infection, CF.

What interventions are being tested in trial NCT01055847?

The interventions under investigation include: Placebo (DRUG), Aztreonam for Inhalation (AI) (DRUG).

Who is sponsoring clinical trial NCT01055847?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01055847 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01055847's enrollment target sits among peer trials

105 58th of 169 higher than 111 of 169 other Cystic Fibrosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03372317 · 105 participants

    Tau PET in Imaging and Cognition: Healthy Adults From 55-90

  • NCT04253964 · 105 participants · Phase 2

    Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

  • NCT04742452 · 105 participants · NA

    Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears

  • NCT04875429 · 105 participants · NA

    Zenith® Fenestrated+ Clinical Study

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01055847, the US trial registry maintained by the National Library of Medicine. NCT01055847 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.